- Home
- BROS vs MIRM Comparison
BROS vs MIRM Comparison
Compare BROS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BROS | MIRM |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.2B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BROS | MIRM |
|---|---|---|
| Price | $40.93 | $80.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 14 |
| Target Price | $70.72 | ★ $153.07 |
| AVG Volume (30 Days) | ★ 4.1M | 818.1K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.24 | 74.59 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,638,159,000.00 | $19,138,000.00 |
| Revenue This Year | $30.12 | $33.62 |
| Revenue Next Year | $24.71 | $17.72 |
| P/E Ratio | $100.37 | ★ N/A |
| Revenue Growth | ★ 27.88 | N/A |
| 52 Week Low | $36.51 | $63.23 |
| 52 Week High | $74.02 | $130.00 |
Technical Indicators
Market Signals| Indicator | BROS | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 37.15 |
| Support Level | $37.40 | $77.78 |
| Resistance Level | $59.07 | $104.56 |
| Average True Range (ATR) | 1.43 | 4.00 |
| MACD | 0.76 | 0.17 |
| Stochastic Oscillator | 68.01 | 20.75 |
Price Performance
Historical ComparisonAbout BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies, and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company-operated shops.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.